Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
Sangamo Therapeutics (NASDAQ: SGMO) announced it will release Q3 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a public conference call and webcast at 8:30 a.m. ET on November 6, 2025 to review results and provide business updates.
Participants should register in advance to receive a dial‑in number and unique passcode or use the dial‑out option; joining 10 minutes early is recommended. The live webcast link is available in the Investors and Media > Events section of the Sangamo website, and a replay will be posted after the call.
Sangamo Therapeutics (NASDAQ: SGMO) ha annunciato che pubblicherà i risultati finanziari del terzo trimestre 2025 prima dell'apertura del mercato giovedì 6 novembre 2025. L'azienda terrà una conferenza pubblica e una webcast alle 8:30 a.m. ET il 6 novembre 2025 per rivedere i risultati e fornire aggiornamenti sull'attività.
Si consiglia ai partecipanti di registrarsi in anticipo per ricevere un numero di accesso e un codice PASS unico o utilizzare l'opzione di richiamata; è consigliato collegarsi 10 minuti prima. Il link della webcast in diretta è disponibile nella sezione Investitori e Media > Eventi del sito Sangamo, e una replica sarà pubblicata dopo la chiamata.
Sangamo Therapeutics (NASDAQ: SGMO) anunció que publicará los resultados financieros del tercer trimestre de 2025 antes de la apertura del mercado el jueves 6 de noviembre de 2025. La compañía organizará una conferencia de prensa pública y una transmisión web en directo a las 8:30 a. m. ET el 6 de noviembre de 2025 para revisar los resultados y ofrecer actualizaciones comerciales.
Se recomienda a los participantes registrarse con antelación para recibir un número de marcación y un código de acceso único o usar la opción de marcación saliente; se recomienda unirse 10 minutos antes. El enlace de la transmisión en vivo está disponible en la sección de Inversores y Medios > Eventos del sitio de Sangamo, y se publicará una repetición después de la llamada.
Sangamo Therapeutics (NASDAQ: SGMO)는 2025년 11월 6일 목요일 시장 개장 전에 2025년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 결과를 검토하고 비즈니스 업데이트를 제공하기 위해 2025년 11월 6일 오전 8시 30분(동부 표준시, ET)에 공개 컨퍼런스 콜과 웹캐스트를 주최합니다.
참석자들은 미리 등록하여 다이얼인 번호와 고유 패스코드를 받거나 발신 옵션을 이용해야 하며, 10분 일찍 참가하는 것이 권장됩니다. 라이브 웹캐스트 링크는 Sangamo 웹사이트의 Investors and Media > Events 섹션에서 확인 가능하며, 콜 종료 후 재생이 게시됩니다.
Sangamo Therapeutics (NASDAQ : SGMO) a annoncé qu'il publiera les résultats financiers du troisième trimestre 2025 avant l'ouverture du marché, le jeudi 6 novembre 2025. La société organisera une conférence téléphonique publique et une webdiffusion à 8h30, heure de l'Est (ET), le 6 novembre 2025 pour examiner les résultats et fournir des mises à jour sur les activités.
Les participants doivent s'inscrire à l'avance pour recevoir un numéro d'appel et un code d'accès unique ou utiliser l'option d'appel sortant ; il est recommandé de se connecter 10 minutes avant. Le lien de la webdiffusion en direct est disponible dans la section Investisseurs et Médias > Événements du site Sangamo, et un replay sera publié après l'appel.
Sangamo Therapeutics (NASDAQ: SGMO) gab bekannt, dass die Finanzergebnisse des dritten Quartals 2025 vor Marktöffnung am Donnerstag, dem 6. November 2025 veröffentlicht werden. Das Unternehmen wird eine öffentliche Telefonkonferenz und einen Webcast um 8:30 Uhr ET am 6. November 2025 abhalten, um Ergebnisse zu besprechen und Geschäftsaktualisierungen bereitzustellen.
Teilnehmer sollten sich im Voraus registrieren, um eine Einwahlnummer und einen eindeutigen Passcode zu erhalten oder die Callback-Option zu nutzen; es wird empfohlen, 10 Minuten früher beizutreten. Der Live-Webcast-Link ist im Abschnitt Investoren und Medien > Veranstaltungen der Sangamo-Website verfügbar, und eine Wiederholung wird nach dem Anruf veröffentlicht.
Sangamo Therapeutics (NASDAQ: SGMO) أعلنت أنها ستصدر النتائج المالية للربع الثالث من 2025 قبل افتتاح السوق يوم الخميس 6 نوفمبر 2025. ستستضيف الشركة مكالمة مؤتمر عام وبثًا مباشرًا عبر الويب في الساعة 8:30 صباحًا بتوقيت شرق الولايات المتحدة ET في 6 نوفمبر 2025 لاستعراض النتائج وتقديم تحديثات تجارية.
ينبغي للمشاركين التسجيل مقدمًا للحصول على رقم اتصال ورمز مرور فريد أو استخدام خيار الاتصال بالخارج؛ يُوصى بالانضمام قبل 10 دقائق. رابط البث المباشر متاح في قسم المستثمرين والإعلام > الفعاليات على موقع Sangamo، وسيتم نشر إعادة الظهور بعد المكالمة.
- None.
- None.
RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.
The company will hold a conference call at 8:30 a.m. Eastern on Thursday, November 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference call, accessible under Events.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and X.
Investor Relations
Louise Wilkie
ir@sangamo.com
Media Inquiries
Melinda Hutcheon
media@sangamo.com
FAQ
When will Sangamo Therapeutics (SGMO) release Q3 2025 financial results?
What time is the Sangamo (SGMO) Q3 2025 earnings call and webcast?
How can investors join the Sangamo (SGMO) November 6, 2025 earnings call?
Will a replay of the Sangamo (SGMO) Q3 2025 earnings call be available?
Is pre-registration required for the Sangamo (SGMO) Q3 2025 call and when should I join?
